Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Kristal Tribble

Nurse Practitioner, Gerontology Clinton, SC Nurse Practitioner

NPI 1376931824 CMS profile 10549169

700 Plaza Cir Ste N, Clinton, SC 29325

Open in the dashboard

General payments

$4,439

231 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kristal Tribble of Clinton, SC is reported in the CMS Open Payments database as having received $4,439 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,324 78
2023 General $1,596 84
2022 General $1,444 66
2021 General $74 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristal Tribble
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Kristal Tribble were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Kristal Tribble Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $74 $133 $44–$396 $132
2022 $1,444 $142 $48–$452 $149
2023 $1,596 $158 $53–$482 $160
2024 $1,324 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AstraZeneca Pharmaceuticals LP $709 33 payments
  2. Teva Pharmaceuticals USA, Inc. $549 43 payments
  3. GlaxoSmithKline, LLC. $357 19 payments
  4. ITI, Inc. $333 16 payments
  5. Genzyme Corporation $331 14 payments
  6. Otsuka America Pharmaceutical, Inc. $267 16 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $259 10 payments
  8. Janssen Pharmaceuticals, Inc $257 15 payments
  9. Vanda Pharmaceuticals Inc. $199 11 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $154 7 payments
  11. Other $1,025 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,381 230 payments
  2. Education $57 1 payment
Products named General payments · program years 2021–2024
  1. DUPIXENT $388 15 payments
  2. CAPLYTA $333 16 payments
  3. FASENRA $289 10 payments
  4. TRELEGY ELLIPTA $278 15 payments
  5. GLASSIA $259 10 payments
  6. BREZTRI $221 13 payments
  7. INVEGA SUSTENNA $220 13 payments
  8. REXULTI $215 12 payments
  9. INVEGA TRINZA $205 12 payments
  10. HETLIOZ $199 11 payments
  11. Other $2,371 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,466

Median for Nurse Practitioner: 389

Drug cost

$332,485

Median for Nurse Practitioner: $21,885

Branded share of claims

14.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 72 $251,007
Uzedy Risperidone Brand 14 $29,518
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $9,484
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $8,582
Lurasidone Hcl Generic 49 $6,480
Paliperidone Er Paliperidone Brand 32 $4,180
Quetiapine Fumarate Generic 171 $2,358
Duloxetine Hcl Generic 83 $1,327
Benztropine Mesylate Generic 92 $1,230
Albuterol Sulfate Hfa Albuterol Sulfate Brand 32 $1,167

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$7,650

Medicare's payments for the services billed

Medicare patients

46

Average age 55

Services billed

125

19 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 50%
Depression 41%
Arthritis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $227
$227 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $174
$174 14 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $144
  • Lundbeck LLC $18
$162 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $112
$112 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record